Thomas Weimer
27Patents
7h-index
35Co-inventors
69Inventor score
Filing activity: Nov 24, 1998 → Dec 29, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6248526A | Labeled primer for use in and detection of target nucleic acids | Emerging Cross-Sectional Technologies | 72 | Expired |
| US8283319B2 | Therapeutic application of Kazal-type serine protease inhibitors | Human Necessities | 30 | Active |
| US7939632B2 | Proteolytically cleavable fusion proteins with high molar specific activity | Chemistry; Metallurgy | 26 | Active |
| US6573081B2 | Method for growing circoviruses | Chemistry; Metallurgy | 25 | Expired |
| US8575104B2 | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life | Chemistry; Metallurgy | 14 | Active |
| US8754194B2 | Modified coagulation factors with prolonged in vivo half-life | Chemistry; Metallurgy | 9 | Active |
| US8765915B2 | Modified coagulation factor VIIa with extended half-life | Chemistry; Metallurgy | 7 | Active |
| US9347051B2 | Coagulation factor X polypeptides with modified activation properties | Chemistry; Metallurgy | 5 | Active |
| US7153679B2 | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis | Physics | 5 | Expired |
| US6183999A | Procedure for the detection of high virus concentrations in blood plasma and/or blood serum by means of the polymerase chain reaction | Chemistry; Metallurgy | 5 | Expired |
| US6831167B2 | Mutants of the factor VII-activating protease and detection methods using specific antibodies | Physics | 4 | Expired |
| US9458223B2 | Von willebrand factor variants having improved factor VIII binding affinity | Human Necessities | 2 | Active |
| US9878017B2 | Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto | Chemistry; Metallurgy | 2 | Active |
| US10688157B2 | Truncated von Willebrand factor polypeptides for treating hemophilia | Human Necessities | 1 | Active |
| US10905747B2 | Methods for preparing modified von Willebrand factor | Chemistry; Metallurgy | 1 | Active |
| US9290561B2 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life | Chemistry; Metallurgy | 1 | Active |
| US9249404B2 | Coagulation factor X polypeptides with modified activation properties | Chemistry; Metallurgy | 0 | Active |
| US8828939B2 | Modified vitamin K dependent polypeptides | Chemistry; Metallurgy | 0 | Active |
| US10772936B2 | Methods for preparing modified von Willebrand factor | Chemistry; Metallurgy | 0 | Active |
| US7863009B2 | Mutants of the factor VII-activating protease and detection methods using specific antibodies | Physics | 0 | Active |
| US11814421B2 | Truncated von Willebrand Factor polypeptides for treating hemophilia | Chemistry; Metallurgy | 0 | Active |
| US11890327B2 | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | Human Necessities | 0 | Active |
| US7803569B2 | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations | Physics | 0 | Active |
| US11155601B2 | Modified von Willebrand factor having improved half-life | Human Necessities | 0 | Active |
| US11564976B2 | Methods for preparing modified von Willebrand Factor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.